You are here: Industry Insights > TREMFYA

News List

Crohn’s patients achieve 65 percent clinical remission with Tremfya® EuropeanPharmaceuticalReview
November 18, 2021
Janssen has announced topline results from the Phase II GALAXI 1 clinical trial which showed rates of clinical remission – Crohn’s Disease Activity Index [CDAI]<150 – previously reported at week 12 increased at week...
Tremfya® shows promise in Phase III psoriatic arthritis study EuropeanPharmaceuticalReview
November 03, 2021
Janssen has announced six new analyses of Phase III data from the DISCOVER-1 and DISCOVER-2 clinical trials, which demonstrate Tremfya® (guselkumab) inhibited radiographic progression versus placebo...
J&J's 2Q Pharma Sales Up 17% contractpharma
July 30, 2021
STELARA and DARZALEX sales drive growth with sales up 34% to $2.3 billion and up 59% to $1.4 billion in the quarter, respectively.
Johnson & Johnson reports 27.1% increase in Q2 2021 sales pharmaceutical-technology
July 23, 2021
Johnson & Johnson (J&J) has reported sales of $23.31bn in the second quarter (Q2) of 2021, an increase of 27.1% compared to $18.33bn in the same quarter last year.
Tremfya® improves psoriatic arthritis joint function and skin clearance europeanpharmaceuticalreview
June 08, 2021
Over 50 percent of psoriatic arthritis patients treated with Tremfya® (guselkumab) achieved ≥20 percent improvement in joint symptoms and complete skin clearance at one year.
J&J’s Tremfya shows significant improvements for post-TNFi psoriatic arthritis patients pharmatimes
June 04, 2021
Johnson & Johnson’s (J&J) interleukin-23 (IL-23) Tremfya has demonstrated positive results in post-tumour necrosis factor (TNF) inhibitor-treated psoriatic arthritis (PsA) patients.
NICE green lights Tremfya to treat active psoriatic arthritis pharmatimes
June 01, 2021
Janssen’s IL-23 inhibitor Tremfya has been accepted for NHS use by the UK’s National Institute for Health and Care Excellence (NICE) for the treatment of active psoriatic arthritis (PsA).
Johnson & Johnson 1Q Results contractpharma
April 21, 2021
Pharmaceutical sales up 10% in the quarter driven by DARZALEX, STELARA, INVEGA SUSTENNA, and IMBRUVICA.
Data shows long-term efficacy of Tremfya® in active psoriatic arthritis europeanpharmaceuticalreview
March 18, 2021
The joint and skin response rates of adults with active psoriatic arthritis observed with Tremfya® (guselkumab) were maintained over two years.
Janssen's Tremfya approved for active psoriatic arthritis pharmatimes
November 27, 2020
The European Commission has approved Janssen’s Tremfya (guselkumab) as a first-in-class treatment for active psoriatic arthritis (PsA).

Previous page 1 2 3 Next page